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Over the past several decades, we have learned much about
the pathophysiology and therapy for primary mitral regur-
gitation (MR). The term “primary” is used to indicate that
it is an abnormality in the structure of the valve itself that
has led to regurgitation. If severe and prolonged, primary
MR eventually causes myocardial damage, dysfunction, and
death unless the valve is repaired or replaced (1–3).
Much has been learned also of the mechanism of second-
ary MR, a condition in which the valve itself is normal but
abnormalities in left ventricular (LV) volume, function, and
shape have led to MR. In both ischemic and dilated
cardiomyopathy, shifts in papillary muscle position result in
tenting of the mitral valve at closure so that the leaflets do
not co-apt properly, in turn leading to MR (4,5). In
addition, ventricular dilation results in annular enlargement,
which further compounds valve incompetence (6). Conver-
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sion of the LV shape from an ellipsoid to a rounder sphere
exacerbates the problem. It is generally held that MR begets
MR. That is, as a volume overload is added to the
pathophysiologic mix, further increases in annular dimen-
sion and worsening of papillary muscle alignment increase
the amount of leak, setting up a perpetual cycle. This cycle
subsequently has important effects on LV geometry, which
are crucial in understanding the pathophysiology of the
disease (7). Although MR has often been viewed as an
afterload-reducing lesion, the ventricular dilation associated
with MR increases the radius term in the LaPlace equation
(stress  pressure  radius/2  thickness) (8,9). Thus, the
effect of MR on LV geometry is to increase ventricular wall
stress despite the unloading effect of the leak itself. In-
creased load further worsens LV performance, leading to
further hemodynamic compromise.
As much as we know of the proper therapy for primary
MR, we know very little about the best management for
secondary MR. What is clear is that the advent of secondary
MR worsens prognosis (10), but it is unclear whether poorer
outcome stems from the MR itself or is simply a marker for
worsening LV function and heart failure.
In acute primary MR, vasodilators are effective in increas-
ing forward flow by reducing aortic impedance. However,
little is known about their long-term usage. Conversely, in
secondary MR virtually all patients have LV dysfunction,
and many have heart failure. As such, almost all are
receiving or should be receiving angiotensin-converting
enzyme inhibitors. Whether additional vasodilators would
be helpful or harmful is unknown, but it seems unlikely that
intense vasodilator therapy would have a substantial impact.
Thus, in view of the importance of LV geometry in this
disease, it is not surprising that the radius term in the
LaPlace equation has become the focus of both medical
(vasodilators) and mechanical therapies.
It is the LaPlacian radius that is uniquely addressed by
Guy et al. (11) in this issue of the Journal. These investi-
gators created myocardial infarction in three groups of sheep
using a model proven to cause substantial secondary isch-
emic MR. One group was untreated, one group had
received an external wrap before infarction designed to limit
post-infarct dilation, and the third group received a prein-
farction mitral annuloplasty designed to limit the amount of
MR that would eventually develop. In both treated groups,
the MR that developed was mild compared with the
untreated group. However, the wrap group had significantly
less dilation and better LV function that the annuloplasty
group. The implication of these data is that it is the
infarction and the remodeling that follows it that is the
major villain after infarction; thus, the MR might not
represent a target for therapy if indeed it is not the major
culprit. These data are unique and add substantially to what
we know about the significance of post-infarct remodeling
and how MR contributes to it. In essence, Guy et al. (11)
address the question: Once medical therapy is maximized,
should we attack the LaPlacian radius by reducing volume
overload by mitral valve repair or by attempting to prevent
ventricular enlargement using other means, such as external
restraint? At least as far as the issue relates to the ovine
model used in their study, the answer appears clear. Both
the wrap and the annuloplasty limited MR, but it was the
wrap that provided the better outcome.
How do these data translate to our practice for patients
with secondary MR? Do they mean we should abandon
mitral repair in patients with secondary MR in favor of
external constraint? Do they apply only to ischemic MR or
can they be extended to the secondary MR of dilated
cardiomyopathy? How close is ovine pathophysiology to
that seen in humans? The answers are unfortunately not at
all clear. Murkiness is generated by several factors. First, the
study was performed temporally opposite to that which
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usually occurs in humans, where the myopathy and ventric-
ular dilation usually have resulted in severe MR and addi-
tional therapy now is required. In the current study, the
therapeutic devices were in place before the insult occurred,
an event obviously unlikely to occur in our patients. Is the
process the same forward as it is in reverse? For now, no one
knows, but at least in some selected cases mitral repair has
already been demonstrated as being beneficial at least for
secondary end points, such as ejection fraction, symptom
status, and ventricular volume (12). It should be noted,
however, that we have no knowledge yet whether restraint
devices would have been as or even more successful in the
same patients. Another problem to be addressed is that the
annuloplasty group in the current study had a lower ejection
fraction than the restraint group despite similar amounts of
MR. Did the annuloplasty in some way impede perfor-
mance that led to worse outcome, or did restraint provide
better function? Without an uninfarcted annuloplasty con-
trol group and a pure control group, we cannot know for
certain.
Guy et al. (1) have performed a real service in the
understanding of ischemic MR. Their data clearly demon-
strate the importance of post-infarct remodeling in causing
both post-infarction MR and LV dysfunction. Their data
further emphasize the potential for external restraint devices
as a therapy for this problem. However, their studies do not
preclude a potential for benefit from mitral valve repair or
replacement in selected patients. Indeed, annuloplasty has
been of benefit to others at least in terms of LV function. So
far, virtually nothing is known about mortality benefits of
either therapy on this disease, data that should be forth-
coming from randomized trails. In the future, it is likely that
both restraint and valve surgery will be beneficial. The
identification of which patients will benefit from which
therapies has yet to be defined.
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